Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Core Viewpoint - Corbus Pharmaceuticals Holdings, Inc. will participate in the Guggenheim Securities Healthcare Innovation Conference, highlighting its commitment to innovative treatments in oncology and obesity [1][2]. Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [2]. - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [2]. - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [2]. - CRB-913: A peripherally restricted CB1 receptor inverse agonist for obesity treatment [2]. - Corbus is headquartered in Norwood, Massachusetts [2]. Event Details - The Guggenheim Securities Healthcare Innovation Conference will take place from November 11-13, 2024, with a specific fireside chat and one-on-one investor meetings scheduled for November 12, 2024, at 10:00 a.m. ET [1][2].